Showing 2241-2250 of 5771 results for "".
- Bausch + Lomb Announces New Scientific and Clinical Analyses to be Presented at AAOhttps://modernod.com/news/bausch-lomb-announces-new-scientific-and-clinical-analyses-to-be-presented-at-aao/2476944/Bausch + Lomb announced that eight new scientific poster and clinical presentations involving the company’s products, as well as data from the company’s Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) surveillance study, will be presented during the annual meeting of the America
- Kodiak Sciences Announces Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at AAOhttps://modernod.com/news/kodiak-sciences-announces-presentation-of-durability-data-from-clinical-development-program-of-ksi-301-in-wet-amd-dme-and-rvo-at-aao/2476945/Kodiak Sciences announced that Charles C. Wykoff, MD, PhD, will present first-time results at the annual mneeting of the American Academy of Ophthalmology (AAO) to be held in San Francisco. The Retina Subspecialty Day (
- TECLens and SERVImed Industrial Spa Announce Partnership to Pursue FDA Approval for Transepithelial Corneal Cross-Linkinghttps://modernod.com/news/teclens-and-servimed-industrial-spa-announce-partnership-to-pursue-fda-approval-for-trans-epithelial-corneal-cross-linking/2476941/Medical device manufacturer TECLens announced a partnership with Italian medical device maker SERVimed Industrial Spa aimed at the development and FDA approval of a new combination product to treat keratoconus. The ne
- Allergan to Showcase Late-Stage Data in AMD and Glaucoma at AAO Annual Meetinghttps://modernod.com/news/allergan-to-showcase-late-stage-data-in-amd-and-glaucoma-at-aao-annual-meeting/2476935/Allergan will present new data from investigational abicipar and bimatoprost sustained release (SR) at the annual meeting of the American Academy of Ophthalmology (AAO) to be held in San Francisco, California. The Retina Subspecialty Day (Oc
- EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for Yutiq Now in Effecthttps://modernod.com/news/eyepoint-pharmaceuticals-announces-permanent-and-specific-j-code-for-yutiq-now-in-effect/2476934/EyePoint Pharmaceuticals announced that the company’s permanent and specific J-Code for Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year microinsert for chronic, noninfectious uveitis affecting the posterior segment of the eye is now in effect. The code, J7314, was issued by the
- Fight For Sight and Prevent Blindness Announce Call for Entries for the 2020 Joanne Angle Public Health Awardhttps://modernod.com/news/fight-for-sight-and-prevent-blindness-announce-call-for-entries-for-the-2020-joanne-angle-public-health-award/2476933/National non-profit organizations Fight for Sight and Prevent Blindness are announcing a call for applications for the Joanne Angle Public Health Award, a $25,000 grant to support a public health research project seeking to put an end to unnecessary vision loss. The award was named for Ms
- Novartis and Microsoft Announce Collaboration to Transform Medicine with Artificial Intelligencehttps://modernod.com/news/novartis-and-microsoft-announce-collaboration-to-transform-medicine-with-artificial-intelligence/2476932/Novartis announced a step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science partner for this effort, according to a company news release. The new lab aims to bolster Novartis AI capabilities from research through com
- Ocular Therapeutix Announces Permanent J-Code for Dextenza Effective October 1, 2019https://modernod.com/news/ocular-therapeutix-announces-permanent-j-code-for-dextenza-effective-october-1-2019/2476930/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent product-specific J-code for Dextenza (dexamethasone ophthalmic insert) 0.4mg for intracanalicular use. Under the Healthcare Common Procedure Coding System (HCPCS), the J-code (J1096) will
- Second Sight Announces $2.4 Million, 4-Year Grant from NIH to Develop Spatial Localization and Mapping Technologyhttps://modernod.com/news/second-sight-announces-2-4-million-4-year-grant-from-nih-to-develop-spatial-localization-and-mapping-technology/2476926/Second Sight Medical Products announced receipt of a $2.4 million, 4-year grant from the National Institutes of Health (NIH) to develop spatial localization and mapping technology (SLAM). A joint collaboration with the Johns Hopkins University Applied Physics Laboratory (APL), the initiative is i
- Ocugen Announces Completion of its Merger with Histogenics to Create Ocular Gene Therapies and Biotherapeuticshttps://modernod.com/news/ocugen-announces-completion-of-its-merger-with-histogenics-to-create-ocular-gene-therapies-and-biotherapeutics/2476924/Ocugen announced the completion of its merger with Histogenics, and the change of the combined company’s name to “Ocugen, Inc.” Ocugen is expected to begin trading today on The Nasdaq Capital Market under the ticker symbol “OCGN.” The executive team of Ocugen has become the executive team of the